| Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. | |
| | |
MedLine Citation:
|
PMID: 20553388 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The PROLONG randomized study showed that patients with an abnormal D-dimer after anticoagulation suspension for a first unprovoked episode of venous thromboembolism (VTE) benefited from anticoagulation resumption. Patients with normal D-dimer after anticoagulation suspension had a low recurrence rate (4.4% patient-years) but their anticoagulation optimal duration remained uncertain. OBJECTIVES: To assess whether sex and age, in combination with normal D-dimer, are risk factors for VTE recurrence in patients enrolled in the PROLONG study extended follow-up. METHODS: D-dimer was measured at 1 month after anticoagulation suspension. Patients with a normal D-dimer did not resume anticoagulants, whereas patients with an abnormal D-dimer were randomized either to resume or not anticoagulants. Primary outcome was recurrent VTE. RESULTS: After excluding patients resuming anticoagulants for abnormal D-dimer, recurrences were higher in males than females [7.4% patient-years - 47/639 vs. 4.3% patient-years - 27/626; hazard ratio (HR) = 1.7; P = 0.027] and in patients aged 65 or older than in younger patients (8.4% patient-years - 50/598 vs. 3.6% patient-years - 24/667; HR = 2.1; P = 0.003). In patients with normal D-dimer and younger than 65, recurrences were higher in males than in females (5.1% vs. 0.4% patient-years; adjusted HR = 10.6; P = 0.023) and both females and males aged 65 years or older had more recurrences (6.6% and 8.1% patient-years, respectively, adjusted HR: 16.0; P = .008 and 16.0; P = 0.008, respectively) than females younger than 65. CONCLUSIONS: In patients with idiopathic VTE and a normal D-dimer at 1 month after anticoagulation suspension, females younger than 65 had a very low risk of recurrence. |
| | |
Authors:
|
B Cosmi; C Legnani; A Tosetto; V Pengo; A Ghirarduzzi; S Testa; D Prisco; D Poli; A Tripodi; G Palareti; |
Related Documents
:
|
19725008 - From dyspnea to pulmonary embolism. 8198328 - Deep venous thrombosis in the trauma patient. 16151418 - Prevalence of inherited prothrombotic abnormalities and central venous catheter-related... 2918628 - Mesenteric venous thrombosis. 20560808 - Ferritin concentrations in synovial fluid are higher in osteoarthritis patients with hf... 19786778 - Performance of fdg pet for detection of alzheimer's disease in two independent multicen... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of thrombosis and haemostasis : JTH Volume: 8 ISSN: 1538-7836 ISO Abbreviation: J. Thromb. Haemost. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-10-28 Completed Date: 2011-02-23 Revised Date: 2011-03-28 |
Medline Journal Info:
|
Nlm Unique ID: 101170508 Medline TA: J Thromb Haemost Country: England |
Other Details:
|
Languages: eng Pagination: 1933-42 Citation Subset: IM |
Copyright Information:
|
© 2010 International Society on Thrombosis and Haemostasis. |
Affiliation:
|
Department of Angiology & Blood Coagulation Marino Golinelli, S.Orsola-Malpighi University Hospital, Bologna, Italy. benilde.cosmi@unibo.it |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00264277 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age Factors Aged Anticoagulants / therapeutic use* Female Fibrin Fibrinogen Degradation Products / therapeutic use* Follow-Up Studies Humans Male Middle Aged Recurrence Risk Risk Factors Sex Factors Time Factors Treatment Outcome Venous Thromboembolism / blood*, therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Fibrin Fibrinogen Degradation Products; 0/fibrin fragment D |
| Investigator | |
Investigator/Affiliation:
|
G Palareti / ; B Cosmi / ; C Legnani / ; C Brusi / ; S Testa / ; A Alatri / ; A Ghirarduzzi / ; A Iorio / ; A Tosetto / ; V Pengo / ; C Pegoraro / ; S Iliceto / ; S Siragusa / ; D Prisco / ; D Poli / ; F Baudo / ; R Cappelli / ; N Erba / ; L La Rosa / ; C Pattacini / ; R Quintavalla / ; L Ria / ; E Bucherini / ; E Cerè / ; V Rossi / ; E Tiraferri / ; C Agazzi / ; S Maria / ; C Villani / ; L Frigerio / ; G Scapoli / ; A Trifiletti / ; M Molinatti / ; P Dori Faccini / ; R Santi / ; G Lessiani / ; V Scarmozzino / ; V Imbimbo / ; A Schenone / ; G Palareti / ; B Cosmi / ; C Legnani / ; A Tosetto / ; A Tripodi / ; A Iorio / ; S Testa / ; A Ghirarduzzi / ; C Pattacini / ; V Pengo / |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Estimating the risk of Amazonian forest dieback.
Next Document: Increased representation of the PTPN22 mutation in patients with immune thrombocytopenia.